Literature DB >> 8605252

Regulation of differential expression of platelet-derived growth factor alpha- and beta-receptor mRNA in normal and malignant human mesothelial cell lines.

A W Langerak1, C A van der Linden-van Beurden, M A Versnel.   

Abstract

In earlier studies we showed that the expression of patterns of platelet-derived growth factor (PDGF) alpha- and beta-receptors differ between normal and malignant mesothelial cell lines. Normal mesothelial cells predominantly express PDGF alpha-receptor mRNA and protein, whereas most malignant mesothelioma cell lines produce PDGF beta-receptor mRNA and protein. In this paper we studied regulation of this differential PDGF receptor mRNA expression. Such an analysis is of importance in view of the suggested PDGF autocrine activity involving the PDGF beta-receptor mesothelioma cells. The results obtained in this study demonstrate that malignant mesothelioma cell lines are not only capable of PDGF beta-receptor transcription but of alpha-receptor transcription as well, as evidenced from run off analysis and RT-PCR using alpha-receptor specific primers. However, the fact that PDGF alpha-receptor mRNA could not be detected by Northern blot analysis, even after cycloheximide treatment, suggests a difference in steady-state PDGF alpha-receptor mRNA expression levels between normal and malignant mesothelial cell lines, which is likely to be caused by a post-transcriptional mechanism. In normal mesothelial cells a half-life of more than 6 h was observed for PDGF alpha-receptor mRNA. In the majority of malignant mesothelioma cell lines clear PDGF beta-receptor mRNA expression was seen. The half-life of the PDGF beta-receptor transcript was at least 6 h in these cells. In contrast, hardly any PDGF beta-receptor transcription was observed in run off assays in normal mesothelial cells, suggesting that differences in beta-receptor transcriptional initiation most probably account for the inability to clearly detect PDGF beta-receptor transcripts in these cells. Transforming growth factor beta-1 (TGF-beta 1), which is being produced in active form by mesothelial cells was evaluated for its potential role in regulation of the differential PDGF receptor expression in these cells. Stimulation with TGF-beta 1 revealed decreased PDGF alpha-receptor mRNA expression in normal mesothelial cells. The effect on PDGF beta-receptor mRNA in the malignant mesothelioma cell lines was variable. Although the TGF-beta 1 effect cannot entirely explain the differential PDGF receptor expression pattern, TGF-beta 1 may nevertheless play a role in downregulation of an (already) low PDGF alpha-receptor mRNA level in malignant mesothelioma cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605252     DOI: 10.1016/0167-4781(95)00196-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

Review 1.  Novel targeted therapies and vaccination strategies for mesothelioma.

Authors:  Mamta Bagia; Anna K Nowak
Journal:  Curr Treat Options Oncol       Date:  2011-06

Review 2.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from human peritoneal tissue.

Authors:  K Shibata; F Kikkawa; A Nawa; K Tamakoshi; N Suganuma; Y Tomoda
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

4.  A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).

Authors:  Kaushal Parikh; Sumithra J Mandrekar; Katie Allen-Ziegler; Brandt Esplin; Angelina D Tan; Benjamin Marchello; Alex A Adjei; Julian R Molina
Journal:  Oncologist       Date:  2019-12-24

5.  Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

Authors:  Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

6.  Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

Authors:  Pietro Bertino; Camillo Porta; Dario Barbone; Serena Germano; Sara Busacca; Sabrina Pinato; Giancarlo Tassi; Roberto Favoni; Giovanni Gaudino; Luciano Mutti
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

Review 7.  Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

Authors:  J F Lechner; J Tesfaigzi; B I Gerwin
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

Review 8.  Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies.

Authors:  Angela Bononi; Andrea Napolitano; Harvey I Pass; Haining Yang; Michele Carbone
Journal:  Expert Rev Respir Med       Date:  2015-08-26       Impact factor: 3.772

9.  Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; J Jack Lee; John Heymach; Katherine Pisters; Waun Ki Hong; Junya Fujimoto; Ignacio Wistuba
Journal:  Clin Lung Cancer       Date:  2013-12-27       Impact factor: 4.785

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.